Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Novartis Unit Developing Denosumab For Osteoporosis

 
• By Dean Rudge
  
Businessmen_Leapfrog
Sandoz believes its biosimilar program is the most advanced globally • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products